Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening

Background & Aims: Two European randomized trials (N = 30,000) compared guaiac fecal occult blood testing with quantitative fecal immunochemical testing (FIT) and showed better attendance rates and test characteristics for FIT. We aimed to identify the most cost-effective FIT cutoff level for re...

Full description

Bibliographic Details
Main Authors: Wilschut, J., Hol, L., Dekker, E., Jansen, J., Van Leerdam, M., Lansdorp_Vogelaar, Iris, Kuipers, E., Habbema, J., Van Ballegooijen, M.
Format: Journal Article
Published: W.B. Saunders Co. 2011
Online Access:http://hdl.handle.net/20.500.11937/49861
_version_ 1848758333716037632
author Wilschut, J.
Hol, L.
Dekker, E.
Jansen, J.
Van Leerdam, M.
Lansdorp_Vogelaar, Iris
Kuipers, E.
Habbema, J.
Van Ballegooijen, M.
author_facet Wilschut, J.
Hol, L.
Dekker, E.
Jansen, J.
Van Leerdam, M.
Lansdorp_Vogelaar, Iris
Kuipers, E.
Habbema, J.
Van Ballegooijen, M.
author_sort Wilschut, J.
building Curtin Institutional Repository
collection Online Access
description Background & Aims: Two European randomized trials (N = 30,000) compared guaiac fecal occult blood testing with quantitative fecal immunochemical testing (FIT) and showed better attendance rates and test characteristics for FIT. We aimed to identify the most cost-effective FIT cutoff level for referral to colonoscopy based on data from these trials and allowing for differences in screening ages. Methods: We used the validated MIcrosimulation SCreening ANalysis (MISCAN)-Colon microsimulation model to estimate costs and effects of different screening strategies for FIT cutoff levels of 50, 75, 100, 150, and 200 ng/mL hemoglobin. For each cutoff level, screening strategies were assessed with various age ranges and screening intervals. We assumed sufficient colonoscopy capacity for all strategies. Results: At all cost levels, FIT screening was most effective with the 50 ng/mL cutoff level. The incremental cost-effectiveness ratio of biennial screening between ages 55 and 75 years using FIT at 50 ng/mL, for example, was 3900 euro per life year gained. Annual screening had an incremental cost-effectiveness ratio of 14,900 euro per life year gained, in combination with a wider age range (between ages 45 and 80 years). In the sensitivity analysis, 50 ng/mL remained the preferred cutoff level. Conclusions: FIT screening is more cost-effective at a cutoff level of 50 ng/mL than at higher cutoff levels. This supports the recommendation to use FIT at a cutoff level of 50 ng/mL, which is considerably lower than the values used in current practice. © 2011 AGA Institute.
first_indexed 2025-11-14T09:42:20Z
format Journal Article
id curtin-20.500.11937-49861
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:42:20Z
publishDate 2011
publisher W.B. Saunders Co.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-498612017-09-13T15:49:09Z Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening Wilschut, J. Hol, L. Dekker, E. Jansen, J. Van Leerdam, M. Lansdorp_Vogelaar, Iris Kuipers, E. Habbema, J. Van Ballegooijen, M. Background & Aims: Two European randomized trials (N = 30,000) compared guaiac fecal occult blood testing with quantitative fecal immunochemical testing (FIT) and showed better attendance rates and test characteristics for FIT. We aimed to identify the most cost-effective FIT cutoff level for referral to colonoscopy based on data from these trials and allowing for differences in screening ages. Methods: We used the validated MIcrosimulation SCreening ANalysis (MISCAN)-Colon microsimulation model to estimate costs and effects of different screening strategies for FIT cutoff levels of 50, 75, 100, 150, and 200 ng/mL hemoglobin. For each cutoff level, screening strategies were assessed with various age ranges and screening intervals. We assumed sufficient colonoscopy capacity for all strategies. Results: At all cost levels, FIT screening was most effective with the 50 ng/mL cutoff level. The incremental cost-effectiveness ratio of biennial screening between ages 55 and 75 years using FIT at 50 ng/mL, for example, was 3900 euro per life year gained. Annual screening had an incremental cost-effectiveness ratio of 14,900 euro per life year gained, in combination with a wider age range (between ages 45 and 80 years). In the sensitivity analysis, 50 ng/mL remained the preferred cutoff level. Conclusions: FIT screening is more cost-effective at a cutoff level of 50 ng/mL than at higher cutoff levels. This supports the recommendation to use FIT at a cutoff level of 50 ng/mL, which is considerably lower than the values used in current practice. © 2011 AGA Institute. 2011 Journal Article http://hdl.handle.net/20.500.11937/49861 10.1053/j.gastro.2011.07.020 W.B. Saunders Co. restricted
spellingShingle Wilschut, J.
Hol, L.
Dekker, E.
Jansen, J.
Van Leerdam, M.
Lansdorp_Vogelaar, Iris
Kuipers, E.
Habbema, J.
Van Ballegooijen, M.
Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
title Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
title_full Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
title_fullStr Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
title_full_unstemmed Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
title_short Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
title_sort cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening
url http://hdl.handle.net/20.500.11937/49861